Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21604724 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2HSP90AA1ESR2TDP1ALDH1A1 | |
| SCHEMBL21096776 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL21096667 | 0.76 | HDAC6 (0.41) | SMN1; SMN2HSP90AA1ESR2TDP1ALDH1A1 | |
| SCHEMBL21096509 | 0.76 | HCAR3 (0.46) | HSP90AA1ESR2TDP1ALDH1A1HPGD | |
| SCHEMBL18764092 | 0.75 | HDAC6 (0.54) | SMN1; SMN2ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL2756735 | 0.74 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1POLBHPGDKDM4E | |
| SCHEMBL28631047 | 0.74 | GUSB (0.53) | HDAC6MGAMIKBKETBK1DHODH | |
| SCHEMBL7214667 | 0.73 | TDP1 (0.51) | SMN1; SMN2HSP90AA1ESR2TDP1ALDH1A1 | |
| SCHEMBL21096665 | 0.73 | MCHR1 (0.36) | SMN1; SMN2HSP90AA1ESR2TDP1ALDH1A1 | |
| SCHEMBL20909800 | 0.73 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1POLBHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145930-B1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | Celon Pharma Sa (PL) | 2018-07-04 | — | — | EP | disclosed |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2017-04-27 | — | — | US | disclosed |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2017-04-27 | — | — | US | disclosed |
| WO-2015177688-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2015-11-26 | — | — | WO | disclosed |
| US-6610692-B1 | Anticoagulants | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1124822-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1124822-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | PDE3B, PDE3A, PDE5A | SMN1; SMN2 2730/4885HSP90AA1 4148/4885ESR2 3973/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | SMN1; SMN2 4778/4885HSP90AA1 3862/4885ESR2 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.